摘要
糖尿病是由多种原因引起的β细胞功能减退,致胰岛素分泌相对或绝对不足引起的糖代谢紊乱,最终导致全身多器官损害。胰岛素的应用虽能明显改善患者的糖代谢紊乱,但却给患者生活带来极大的不便。胰岛移植可以解决每日胰岛素注射的问题,但供体的有限及免疫排斥反应使糖尿病的治疗受到了限制。若利用能分泌胰岛素的细胞(如诱导分化的干细胞)移植来治疗糖尿病无疑为糖尿病的有效治疗提供了新的思路,但是宿主对异源性细胞产生的移植排斥反应却是其在临床上应用的主要障碍。微囊的选择透过性一方面可对微囊化细胞进行免疫保护,另一方面又不影响其胰岛素的分泌,从而实现细胞的同种或异种移植,应用前景良好。
Diabetes mellitus （hypofunction of beta cells） is a group of metabolic diseases characterized by high glucose level, which result from defects in insulin secretion, or action, or both. Diabetes mellitus can lead to multiple organ lesions in late stage Although the application of insulin can improve glucose metabolism in patients with the disorder, it brings great inconvenience to the lives of patients. Islet transplantation can solve the problem of daily insulin injections, but the donor＇s immune rejection and the treatment of diabetes have been restricted. It is no doubt that the use of cells transplantation, which can secrete insulin to treat diabetes, such as differentiation of stem cells, provides an effective treatment for diabetes a new way. However, the transplant rejection from the host＇s immune system against heterogeneous cells has been the main handicap of its clinical application, Based on the perms elective property of microcapsule membrane, encapsulated cells can be immune-protected and unaffected insulin secretion to realize allo- or homo- transplantation. It has been shown potential application foreground.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2008年第32期6335-6338,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
